L&C BIO CO., LTD L&C Bio Co., Ltd Share Price
Equities
A290650
KR7290650001
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19,650 KRW | -1.65% |
|
-4.15% | -32.24% |
| Sales 2022 | 52.57B 38.22M 3.18B | Sales 2023 | 68.87B 50.07M 4.17B | Capitalization | 658B 478M 39.85B |
|---|---|---|---|---|---|
| Net income 2022 | 4.54B 3.3M 275M | Net income 2023 | 48.36B 35.16M 2.93B | EV / Sales 2022 | 11.3 x |
| Net Debt 2022 | 69.63B 50.62M 4.22B | Net Debt 2023 | 22.94B 16.68M 1.39B | EV / Sales 2023 | 9.89 x |
| P/E ratio 2022 |
116
x | P/E ratio 2023 |
13.8
x | Employees | 121 |
| Yield 2022 |
0.22% | Yield 2023 |
0.34% | Free-Float | 68.64% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.65% | ||
| 1 week | -4.15% | ||
| Current month | -15.67% | ||
| 1 month | -17.44% | ||
| 3 months | -19.80% | ||
| 6 months | -31.17% | ||
| Current year | -32.24% |
1 week
19 600.00
21 000.00
1 month
19 600.0024 350.00
Current year
19 600.0029 500.00
1 year
19 600.0041 700.00
3 years
17 350.0046 700.00
5 years
4 983.3351 866.67
10 years
4 983.3351 866.67
| Managers | Title | Age | Since |
|---|---|---|---|
Hwan-Chul Lee
CEO | Chief Executive Officer | 48 | - |
Hyung-Gu Kim
BRD | Director/Board Member | 57 | - |
Jong-Oh Choi
AUD | Comptroller/Controller/Auditor | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hwan-Chul Lee
CEO | Chief Executive Officer | 48 | - |
Hyung-Gu Kim
BRD | Director/Board Member | 57 | - |
Hae-Seok Hwang
BRD | Director/Board Member | 68 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 19,650 | -1.65% | 111,126 |
| 25/24/25 | 19,980 | -2.54% | 73,825 |
| 24/24/24 | 20,500 | +1.49% | 35,269 |
| 23/24/23 | 20,200 | -0.25% | 65,960 |
| 22/24/22 | 20,250 | -1.22% | 104,660 |
End-of-day quote Korea S.E., April 26, 2024
More quotes
L&C BIO Co., Ltd is a Korea-based Company mainly engaged in the regenerative medicine business. The Company mainly manufactures and sells human tissue transplant materials used for tissue repair and filler. The Company also produces and sells human tissue-based medical devices and Cosmeceuticals. Its products are used in vascular surgeries, plastic surgeries, general surgeries and others.
Calendar
14/05/2024
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -32.24% | 324M | |
| +12.07% | 128B | |
| -9.04% | 10.65B | |
| +0.91% | 8.82B | |
| +16.72% | 7.19B | |
| +25.15% | 4.99B | |
| +7.17% | 3.4B | |
| -1.36% | 3.03B | |
| -8.73% | 2.14B | |
| -10.15% | 2B |
- Stock Market
- Equities
- A290650 Stock
